• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in endocrinology and metabolism. >Immunotherapy-induced endocrinopathies: assessment, management and monitoring
【24h】

Immunotherapy-induced endocrinopathies: assessment, management and monitoring

机译：免疫疗法诱导的内分泌术：评估，管理和监测

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy with checkpoint inhibitors has transformed the treatment of cancer, but frequently results in immune-mediated adverse events affecting multiple organs, amongst which endocrine adverse events are frequent. The patterns of endocrine adverse events differ between inhibitors of the CTLA-4 and PD-1/PD-L1 pathways, but most frequently involve the thyroid and pituitary with insulin deficient diabetes also emerging as an important adverse event. These frequently result in long-lasting hormone deficiency requiring replacement. This review explores the mechanism of action of checkpoint inhibitors and details the expected endocrine adverse events and typical presentations. The effect of high-dose glucocorticoids therapy to treat nonendocrine adverse events is also discussed.
机译：用检查点抑制剂的免疫疗法转化了癌症的治疗，但经常导致影响多个器官的免疫介导的不良事件，其中内分泌不良事件频繁。内分泌不良事件的模式在CTLA-4和PD-1 / PD-L1途径的抑制剂之间不同，但大多数经常涉及甲状腺和垂体，胰岛素缺乏糖尿病也被出现为重要的不良事件。这些经常导致需要更换的持久激素缺乏症。本综述探讨了检查点抑制剂的作用机制，并详细说明了预期的内分泌不良事件和典型的演示。还讨论了高剂量糖皮质激素治疗治疗非内分泌不良事件的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号